http://www.cnr.it/ontology/cnr/individuo/prodotto/ID267531

Detection of high levels of Survivin-IgM immune complex in sera from hepatitis C virus infected patients with cirrhosis. (Articolo in rivista)

Type

Articolo in rivista (Classe)
Prodotto della ricerca (Classe)

Label

Detection of high levels of Survivin-IgM immune complex in sera from hepatitis C virus infected patients with cirrhosis. (Articolo in rivista) (literal)

Anno

2013-01-01T00:00:00+01:00 (literal)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#doi

10.1111/hepr.12239 (literal)

Alternative label

Matteucci C, Sorrentino R, Bellis L, Ettorre GM, Svicher V, Santoro R, Vennarecci G, Biasiolo A, Pontisso P, Scacciatelli D, Beneduce L, Sarrecchia C, Casalino P, Bernardini S, Pierimarchi P, Garaci E, Puoti C, Rasi G. (2013)
Detection of high levels of Survivin-IgM immune complex in sera from hepatitis C virus infected patients with cirrhosis.
in Hepatology research (Print)
(literal)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#autori

Matteucci C, Sorrentino R, Bellis L, Ettorre GM, Svicher V, Santoro R, Vennarecci G, Biasiolo A, Pontisso P, Scacciatelli D, Beneduce L, Sarrecchia C, Casalino P, Bernardini S, Pierimarchi P, Garaci E, Puoti C, Rasi G. (literal)

Rivista

Hepatology research (Rivista)

Note

ISI Web of Science (WOS) (literal)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#affiliazioni

Department of Experimental Medicine and Surgery, University of Rome \"Tor Vergata\", Italy; Institute of Translational Pharmacology, CNR, Rome, Italy. (literal)

Titolo

Detection of high levels of Survivin-IgM immune complex in sera from hepatitis C virus infected patients with cirrhosis. (literal)

Abstract

AIM: The identification and surveillance of patients with liver dysfunctions and the discovering of new disease biomarkers with high sensibility and specificity are needed in the clinical practice. Aim of this study was to investigate on the serological presence of circulating Survivin-IgM immune complex (IC) as potential biomarker of diverse phases of chronic liver diseases. METHODS: Serum levels of Survivin-IgM were measured using an ELISA standardized and validated in our laboratory in 262 individuals, including healthy subjects and patients with chronic hepatitis, cirrhosis and HCC. RESULTS: Survivin-IgM IC was lower in healthy subjects (median: 99.39 AU/ml, IQR=73.33-148.27) than in patients with chronic viral hepatitis (median: 148.03 AU/ml, IQR=86.75-333.82; p=0.002) or with cirrhosis (median: 371.00 AU/ml, IQR=106.07-1110.06; p<0.001). Among patients with cirrhosis, those with hepatitis C virus (HCV) infection showed the highest level of Survivin-IgM IC (median: 633.71 AU/ml, IQR=304.60-2084.07; p<0.001). The ROC curve analysis revealed that Survivin-IgM is accurate in distinguishing HCV correlated cirrhosis from chronic viral hepatitis (AUC=0.738) with a sensitivity of 74.5% and a specificity of 70.7%. A multivariate logistic regression model, including Survivin-IgM IC, AST and AST/ALT ratio (AUC=0.818) increased the prediction accuracy for the identification of the cirrhotic HCV patients (sensitivity 87.2%; specificity 65.9%). Conversely, Survivin-IgM IC significantly decreased in HCC patients (median: 165.72 AU/ml, IQR=101.80-425.41; p=0.022). CONCLUSIONS: Our results suggest that circulating Survivin-IgM immune complex might be used, either alone or in combination with other biomarkers, as potential biomarker for liver damage, particularly for the identification the HCV related cirrhotic population. (literal)

Prodotto di